Sol-Gel Technologies Ltd. (SLGL)

USD 0.73

(-5.68%)

Market Cap (In USD)

20.33 Million

Revenue (In USD)

1.55 Million

Net Income (In USD)

-27.23 Million

Avg. Volume

160.38 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.334-1.575
PE
-2.15
EPS
-0.34
Beta Value
1.603
ISIN
IL0011417206
CUSIP
M8694L103
CIK
1684693
Shares
27857600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alon Seri-Levy
Employee Count
-
Website
https://www.sol-gel.com
Ipo Date
2018-02-01
Details
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.